Schluckauf als Leitsymptom

1.

BBC. Guinness medical record breakers: Longest attack of hiccups: Charles Osborne. www.news.bbc.co.uk

2.

Apiwattanakul M, Popescu BF, Matiello M, Weinshenker BG, Lucchinetti CF, Lennon VA, McKeon A, Carpenter AF, Miller GM, Pittock SJ. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 68(5):757–761, 2010CrossRefPubMed

3.

Krysiak W, Szabowski S, Stepień M, Krzywkowska K, Krzywkowski A, Marciniak P. Hiccups as a myocardial ischemia symptom. Pol Arch Med Wewn 118(3):148–151, 2008PubMed

4.

Lin LF, Huang PT. An uncommon cause of hiccups: sarcoidosis presenting solely as hiccups. J Chin Med Assoc 73: 647–650, 2010CrossRefPubMed

5.

Chang FY, Lu CL. Hiccup: mystery, nature and treatment. J Neurogastroenterol Motil 18(2):123–130, 2012CrossRefPubMedPubMedCentral

6.

Yoshida T, Fujisaki N, Nakachi R, Sueyoshi T, Suwazono S, Suehara M. Persistent hiccups and vomiting with multiple cranial nerve palsy in a case of zoster sine herpete. Intern Med 53(20):2373–2376, 2014CrossRefPubMed

7.

Marsot-Dupuch K, Bousson V, Cabane J, Tubiana JM. Intractable hiccups: the role of cerebral MR in cases without systemic cause. AJNR Am J Neuroradiol 16(10):2093–2100, 1995PubMed

8.

Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera-Gómez JA, Newell K, Mandler RN, Pittock SJ, Weinshenker BG, Lucchinetti CF. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 76(14):1229–1237, 2011CrossRefPubMedPubMedCentral

9.

Gross PM. Morphology and physiology of capillary systems in subregions of the subfornical organ and area postrema. Can J Physiol Pharmacol 69(7):1010–1025, 1991CrossRefPubMed

10.

Duvernoy HM, Risold PY. The circumventricular organs: an atlas of comparative anatomy and vascularization. Brain Res Rev 56(1): 119–147, 2007CrossRefPubMed

11.

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2): 177–189, 2015CrossRefPubMedPubMedCentral

12.

Lennon, V.A.; Wingerchuk, D.M.; Kryzer, T.J.; Pittock, S.J.; Lucchinetti, C.F.; Fujihara, K.; Nakashima, I.; Weinshenker, B.G. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 364: 2106–2112, 2004CrossRefPubMed

13.

Lennon, V.A.; Kryzer, T.J.; Pittock, S.J.; Verkman, A.S.; Hinson, S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473–477, 2005CrossRefPubMedPubMedCentral

14.

Dubey D, Pittock SJ, Krecke KN, Flanagan EP. Association of extension of cervical cord lesion and area postrema syndrome with Neuromyelitis Optica Spectrum Disorder. JAMA Neurol published online January 9, 2017. doi:10.1001/jamaneurol.2016.5441, 2017

15.

Jin X, Pei S, Liu Y, Li X. Clinical analysis of neuromyelitis optica presenting as intractable nausea, vomiting and hiccups. Int J Neurosci 16: 1–5, 2016

16.

Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A. Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. Neurol Neuroimmunol Neuroinflamm 4(2): e317, 2016CrossRefPubMedPubMedCentral

17.

Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, Lassmann H. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66(5): 630–643, 2009CrossRefPubMed

18.

Nishiyama S, Ito T, Misu T, Takahashi T, Kikuchi A, Suzuki N, Jin K, Aoki M, Fujihara K, Itoyama Y. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 72(22): 1960–1961, 2009CrossRefPubMed

19.

Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Shiga Y, Kanaoka C, Fujimori J, Sato S, Itoyama Y. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007 May;130(Pt 5): 1235–1243, 2007CrossRefPubMed

20.

Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4(4): 202–214, 2008PubMed

21.

Qin K, Wu W, Huang Y, Xu D, Zhang L, Zheng B, Jiang M, Kou C, Gao J, Li W, Zhang J, Wang S, Luan Y, Yan C, Xu D, Zheng X. Anti-N-methyl-D-aspartate receptor(NMDAR) antibody encephalitis presents in atypical types and coexists with neuromyelitis optica spectrum disorder or neurosyphilis. BMC Neurol 17(1):1. doi: 10.1186/s12883-016-0787-9, 2017CrossRefPubMedPubMedCentral

22.

Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation 10:8. doi: 10.1186/1742-2094-10-8, 2013PubMedPubMedCentral

23.

Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1014, 1999CrossRefPubMed

24.

Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10): 1485–1489, 2006CrossRefPubMed

25.

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 6(9): 805–815, 2007CrossRefPubMed

26.

Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG. Neuromyelitis optica: changing concepts. J Neuroimmunol 187(1-2): 126–138, 2007CrossRefPubMed

27.

Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 84(11): 1165–1173, 2015CrossRefPubMedPubMedCentral

28.

Solomon AJ, Bourdette DN, Cross AH, et al. The spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteria: a multicenter study. Presented at: The 68th Annual Meeting of the American Academy of Neurology; April 15-21, 2016

29.

Cobo-Calvo Á, Sepúlveda M, Bernard-Valnet R, Ruiz A, Brassat D, Martínez-Yélamos S, Saiz A, Marignier R. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. Mult Scler 22(3): 312–319, 2016CrossRefPubMed

30.

Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, Kleiter I, Chitnis T; GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler 21(7):845–853, 2015CrossRefPubMedPubMedCentral

31.

Collongues N, Marignier R, Jacob A, Leite MI, Siva A, Paul F, Zephir H, Akman-Demir G, Elsone L, Jarius S, Papeix C, Mutch K, Saip S, Wildemann B, Kitley J, Karabudak R, Aktas O, Kuscu D, Altintas A, Palace J, Confavreux C, De Seze J. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler 20(8): 1086–1094, 2014CrossRefPubMed

32.

Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, Rommer P, Kleiter I, Stich O, Reuss R, Rauer S, Zettl UK, Wandinger KP, Melms A, Aktas O, Kristoferitsch W, Wildemann B. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 306(1-2):82–90, 2011CrossRefPubMed

33.

Juryńczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D’hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Sèze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol 263(1): 140–149, 2016CrossRefPubMed

34.

Collongues N, Marignier R, Jacob A, Leite MI, Siva A, Paul F, Zephir H, Akman-Demir G, Elsone L, Jarius S, Papeix C, Mutch K, Saip S, Wildemann B, Kitley J, Karabudak R, Aktas O, Kuscu D, Altintas A, Palace J, Confavreux C, De Seze J. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler 20(8): 1086–1094, 2014CrossRefPubMed

35.

Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, Rommer P, Kleiter I, Stich O, Reuss R, Rauer S, Zettl UK, Wandinger KP, Melms A, Aktas O, Kristoferitsch W, Wildemann B. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 306(1-2):82–90, 2011CrossRefPubMed

36.

Jarius S, Franciotta D, Bergamaschi R, Rauer S, Wandinger KP, Petereit HF, Maurer M, Tumani H, Vincent A, Eichhorn P, Wildemann B, Wick M, Voltz R. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 79(10):1134–1136, 2008CrossRefPubMed

37.

Filippi M, Rocca MA. MR imaging of Devic’s neuromyelitis optica. Neurol Sci 25 Suppl 4:S371–373, 2004CrossRefPubMed

38.

Trebst C, Raab P, Voss EV, Rommer P, Abu-Mugheisib M, Zettl UK, Stangel M. Longitudinal extensive transverse myelitis—it’s not all neuromyelitis optica. Nat Rev Neurol 7(12): 688–698, 2011CrossRefPubMed

39.

Kitley JL, Leite MI, George JS, Palace JA. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler 18(3): 271–285, 2012CrossRefPubMed

40.

Pekcevik Y, Orman G, Lee IH, Mealy MA, Levy M, Izbudak I. What do we know about brain contrast enhancement patterns in neuromyelitis optica? Clin Imaging 40(3): 573–580, 2016a

41.

Krampla W, Aboul-Enein F, Jecel J, Lang W, Fertl E, Hruby W, Kristoferitsch W. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 19(10): 2535–2543, 2009CrossRefPubMed

42.

Kaivorinne AL, Lintunen J, Baumann P. Fulminant neuromyelitis optica in a Finnish woman - a case report. Clin Case Rep 4(8): 782–785, 2016CrossRefPubMedPubMedCentral

43.

Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 63(3): 390–396, 2006CrossRefPubMed

44.

Kim W, Park MS, Lee SH, Kim SH, Jung IJ, Takahashi T, Misu T, Fujihara K, Kim HJ. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 16(10): 1229–1236, 2010CrossRefPubMed

45.

Roy U, Saini DS, Pan K, Pandit A, Ganguly G, Panwar A. Neuromyelitis optica spectrum disorder with tumefactive demyelination mimicking Multiple Sclerosis: A rare case. Front Neurol 7:73, 2016CrossRefPubMedPubMedCentral

46.

Chan KH, Tse CT, Chung CP, Lee RL, Kwan JS, Ho PW, Ho JW. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol 68(11): 1432–1439, 2011CrossRefPubMed

47.

Asgari N, Skejoe HP, Lillevang ST, Steenstrup T, Stenager E, Kyvik KO. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol 13:33, 2013CrossRefPubMedPubMedCentral

48.

Matthews L, Marasco R, Jenkinson M, Küker W, Luppe S, Leite MI, Giorgio A, De Stefano N, Robertson N, Johansen-Berg H, Evangelou N, Palace J. Distinction of seropositive N MO spectrum disorder and MS brain lesion distribution. Neurology 80(14): 1330–1337, 2013CrossRefPubMedPubMedCentral

49.

Wang F, Liu Y, Duan Y, Li K. Brain MRI abnormalities in neuromyelitis optica. Eur J Radiol 80(2): 445–449, 2011CrossRefPubMed

50.

Klawiter EC, Xu J, Naismith RT, Benzinger TL, Shimony JS, Lancia S, Snyder AZ, Trinkaus K, Song SK, Cross AH. Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Mult Scler 18(9): 1259–1268, 2012CrossRefPubMedPubMedCentral

51.

Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD, Thompson CB, Pardo CA, Calabresi PA, Levy M, Izbudak I. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler 22(3): 302–311, 2016bCrossRefPubMed

52.

Banker P, Sonni S, Kister I, Loh JP, Lui YW. Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler 18(7): 1050–1053, 2012CrossRefPubMed

53.

McGraw CA, Swerdlow ML, Robbins MS. Acute reversible periependymal ventricular enhancement in neuromyelitis optica. Eur J Neurol 19(6): e57–58, 2012CrossRefPubMed

54.

Tahara M, Ito R, Tanaka K, Tanaka M. Cortical and leptomeningeal involvement in three cases of neuromyelitis optica. Eur J Neurol 19(5): e47–48, 2012CrossRefPubMed

55.

Flanagan EP, Kaufmann TJ, Krecke KN, Aksamit AJ, Pittock SJ, Keegan BM, Giannini C, Weinshenker BG. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 79(3): 437–447, 2016CrossRefPubMed

56.

Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 10(1): 55–66, 2008CrossRefPubMed

57.

Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17(8): 1019–1032, 2010CrossRefPubMed

58.

Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1): 1–16, 2014CrossRefPubMed

59.

Weinshenker BG. Placebo studies should not be undertaken in neuromyelitis optica: Commentary. Mult Scler 21(6):693–694, 2015 Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 15(4): 487-492, 2009CrossRefPubMed

60.

Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. Placebo-controlled study in neuromyelitis optica - Ethical and design considerations. Mult Scler 22(7): 862–872, 2016CrossRefPubMed

61.

Kleiter I, Gold R. Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics 13(1):70–83, 2016aCrossRefPubMed

62.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K,Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; Neuromyelitis Optica Study Group. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79(2): 206–216, 2016bCrossRefPubMed

63.

Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler 22(2): 185–192, 2016CrossRefPubMed

64.

Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 15(4): 487–492, 2009CrossRefPubMed

65.

Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69(2): 239–245, 2012CrossRefPubMed

66.

Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol 263(1): 25–29, 2016CrossRefPubMed

67.

Shimizu Y, Yokoyama K, Misu T, Takahashi T, Fujihara K, Kikuchi S, Itoyama Y, Iwata M. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 255(2): 305–307, 2008CrossRefPubMed

68.

Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 18(1): 113–115, 2012CrossRefPubMed

69.

Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77(7): 659–666, 2011CrossRefPubMed

70.

Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, Brown R, Moss K, McNeillis B, Goh YY, Leite MI, Robertson N, Palace J, Jacob A. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4-antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 20(11): 1533–1540, 2014CrossRefPubMed

71.

Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71(3): 324–330, 2014CrossRefPubMed

72.

Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17(10): 1225–1230, 2011CrossRefPubMed

73.

Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15): 1310–1315, 2011CrossRefPubMed

74.

Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70(9):1110–1117, 2013CrossRefPubMed

75.

Kim SH, Hyun JW, Joung A, Park EY, Joo J, Kim HJ. Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders. Mult Scler 1:1352458516687403. doi: 10.1177/1352458516687403. [Epub ahead of print], 2017

76.

Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol 72(7): 756–763, 2015CrossRefPubMed

Springer Medizin

Schluckauf als Leitsymptom

Auszug

Passend zum Thema

Services in der MS-Therapie für Neurolog*innen und Betroffene

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Eslicarbazepin jetzt auch für Kinder zugelassen

Zehn Jahre integrierte Versorgung der Psychiatrie Initiative Berlin Brandenburg

Psychotherapeutische Sprechstunde als neue Gesprächsleistung

5,3 Millionen Beschäftigte im Gesundheitswesen

„Gravitation nach dem Unglücke“

Schlaflos durch Mobilfunk?

Passend zum Thema

Services in der MS-Therapie für Neurolog*innen und Betroffene